The Michael J. Fox Foundation Expands Fox Trial Finder to Accelerate Research in Atypical Parkinsonism
MJFF’s online clinical research matching tool, Fox Trial Finder, now includes studies and a registration option for atypical parkinsonism.
KINGSTON, NJ, July 25, 2016 – People with atypical parkinsonism and their loved ones have a new route to research studies toward a deeper understanding of the disease and new treatments. The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has announced the expansion of its clinical research matching tool, Fox Trial Finder, to include studies and a registration option for atypical parkinsonism.
The Parkinson Alliance (umbrella organization for the Parkinson’s Unity Walk, Team Parkinson, and dbs4pd.org), will partner with MJFF to support this expansion of the tool and advance development of new therapies for both Parkinson’s and atypical parkinsonism.
“Because the symptoms are similar to Parkinson’s disease, our organization is hearing more and more from people who are diagnosed with atypical parkinsonism. This expansion to MJFF’s Fox Trial Finder is a valuable addition because hopefully it will also tell us more about Parkinson’s disease,” stated Carol Walton, CEO of The Parkinson Alliance.
The neurodegenerative diseases associated with atypical parkinsonism — corticobasal degeneration, dementia with Lewy bodies, multiple system atrophy and progressive supranuclear palsy — share symptoms and, in some cases, biology with Parkinson’s. Accelerating research into these conditions may help uncover breakthroughs that cross diagnostic lines.
Fox Trial Finder matches registrants to studies on criteria such as geographic location and medical history. Volunteers receive email notifications when new trials launch that need them and can use a built-in messaging function to connect with trial teams. Participants’ privacy is protected by state-of-the-art security protocols, and site content is available in English, French, German, Italian and Spanish.
“There is much to learn about atypical parkinsonisms and their connections to each other and to Parkinson’s disease,” said Todd Sherer, PhD, CEO of MJFF. “Expanding Fox Trial Finder to be more inclusive of these conditions will speed trial recruitment and thereby the pace of discovery and drug development for the millions affected.”
Visit Fox Trial Finder to learn more and register today.
Click for a printer friendly version